← Back to Search

Anti-sense oligonucleotide

STP705 for Squamous Cell Carcinoma (isSCC Trial)

Phase 1 & 2

Waitlist Available

Led By Mark Nestor, MD

Research Sponsored by Sirnaomics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 21 weeks

Awards & highlights

isSCC Trial Summary

This trial is testing how safe a new drug is. People taking part will start with a low dose and then have the dose increased gradually to see how well they tolerate it.

Eligible Conditions

Squamous Cell Carcinoma of the Face

isSCC Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 21 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~21 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 21 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of participants with histological clerance of treated isSCC lesion at the end of treatment

Secondary outcome measures

Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

isSCC Trial Design

3Treatment groups

Experimental Treatment

Group I: STP705 90ugExperimental Treatment1 Intervention

STP705 will be administered once weekly for 6 weeks

Group II: STP705 60ugExperimental Treatment1 Intervention

STP705 will be administered once weekly for 6 weeks

Group III: STP705 30ugExperimental Treatment1 Intervention

STP705 will be administered once weekly for 6 weeks

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

STP705

2022

Completed Phase 2

~180

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

SirnaomicsLead Sponsor

11 Previous Clinical Trials

328 Total Patients Enrolled

Mark Nestor, MDPrincipal InvestigatorCenter for Clinical and Cosmetic Research

3 Previous Clinical Trials

81 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are we still enrolling people in this research project?

"The correct answer is that, according to the information available on clinicaltrials.gov, this study is still recruiting patients as of 8/5/2022. This particular trial was first announced on 8/1/2022 and is currently looking for 30 more participants at a single location."

Answered by AI

How many test subjects are needed for this clinical trial to be completed?

"The clinical trial is currently active and recruiting patients. August 1st, 2022 was the original posting date for the study, with the most recent update being on August 5th, 2022. Only 30 individuals are needed for the study which is taking place at a single location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC

2022. "Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05421013.